54 related articles for article (PubMed ID: 15014897)
1. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women.
Jannuzzo MG; Poggesi I; Spinelli R; Rocchetti M; Cicioni P; Buchan P
Cancer Chemother Pharmacol; 2004 Jun; 53(6):475-81. PubMed ID: 15014897
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment.
Mercier AK; Sunnåker M; Ueckert S; Pawlik T; Henricson E; Molodetskyi O; Law GC; Parker VER; Oscarsson J
Clin Pharmacokinet; 2023 Dec; 62(12):1713-1724. PubMed ID: 37801266
[TBL] [Abstract][Full Text] [Related]
3. A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation.
Valle M; Di Salle E; Jannuzzo MG; Poggesi I; Rocchetti M; Spinelli R; Verotta D
Br J Clin Pharmacol; 2005 Mar; 59(3):355-64. PubMed ID: 15752382
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of the dual melatonin receptor agonist tasimelteon in subjects with hepatic or renal impairment.
Torres R; Kramer WG; Baroldi P
J Clin Pharmacol; 2015 May; 55(5):525-33. PubMed ID: 25450415
[TBL] [Abstract][Full Text] [Related]
5. Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics.
Forgue ST; Phillips DL; Bedding AW; Payne CD; Jewell H; Patterson BE; Wrishko RE; Mitchell MI
Br J Clin Pharmacol; 2007 Jan; 63(1):24-35. PubMed ID: 16869816
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment.
Holmes G; Galitz L; Hu P; Lyness W
Br J Clin Pharmacol; 2005 Nov; 60(5):469-76. PubMed ID: 16236036
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of single-dose oral stavudine in subjects with renal impairment and in subjects requiring hemodialysis.
Grasela DM; Stoltz RR; Barry M; Bone M; Mangold B; O'Grady P; Raymond R; Haworth SJ
Antimicrob Agents Chemother; 2000 Aug; 44(8):2149-53. PubMed ID: 10898689
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of long-acting lenacapavir in participants with hepatic or renal impairment.
Jogiraju V; Weber E; Hindman J; West S; Ling J; Rhee M; Girish S; Palaparthy R; Singh R
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0134423. PubMed ID: 38456707
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Safety Evaluation of Single-Dose Saroglitazar Magnesium in Subjects with Hepatic Impairment.
Lawitz E; Parmar D; Momin T; Shaikh F; Patel H; Hayes H; Swint K
Clin Pharmacol Drug Dev; 2023 Dec; 12(12):1142-1155. PubMed ID: 37909052
[TBL] [Abstract][Full Text] [Related]
10. Hepatic Dysfunction Quantified by HepQuant DuO Outperforms Child-Pugh Classification in Predicting the Pharmacokinetics of Ampreloxetine.
Kanodia J; Giovinazzo H; Yates W; Bourdet DL; McRae MP; Helmke SM; Everson GT
Clin Pharmacol Ther; 2024 Jul; 116(1):186-193. PubMed ID: 38654484
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Safety of Firsocostat, an Acetyl-Coenzyme A Carboxylase Inhibitor, in Participants with Mild, Moderate, and Severe Hepatic Impairment.
Younis IR; Nelson C; Weber EJ; Qin AR; Watkins TR; Othman AA
J Clin Pharmacol; 2024 Mar; ():. PubMed ID: 38520128
[TBL] [Abstract][Full Text] [Related]
12. Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dersimelagon (MT-7117), an Oral Melanocortin-1 Receptor Agonist.
Ogasawara A; Ide R; Inoue S; Teng R; Kawaguchi A
Clin Pharmacol Drug Dev; 2024 May; ():. PubMed ID: 38746989
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine.
Potocka E; Cassidy JP; Haworth P; Heuman D; van Marle S; Baughman RA
J Diabetes Sci Technol; 2010 Sep; 4(5):1164-73. PubMed ID: 20920436
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Various Degrees of Renal or Hepatic Impairment on the Pharmacokinetic Properties of Once-Weekly Insulin Icodec.
Haahr H; Cieslarová B; Hingst JR; Jiang S; Kristensen NR; Kupčová V; Nørgreen L; Wagner FH; Ignatenko S
Clin Pharmacokinet; 2024 May; ():. PubMed ID: 38722461
[TBL] [Abstract][Full Text] [Related]
15. CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial.
Solomon SR; Powell BL; Koprivnikar J; Lai C; Male H; Michaelis LC; Newell LF; Sanford D; Jenkins J; Zelaya A; Coppola S; Faderl S; Walter RB
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473278
[TBL] [Abstract][Full Text] [Related]
16. Dose Volume and Liver Function Test Relationship following Radiotheraphy for Right Breast Cancer: A Multicenter Study.
Güzelöz Z; Ayrancıoğlu O; Aktürk N; Güneş M; Alıcıkuş ZA
Curr Oncol; 2023 Sep; 30(10):8763-8773. PubMed ID: 37887532
[TBL] [Abstract][Full Text] [Related]
17. Influence of Glutathione-S-Transferase A1*B Allele on the Metabolism of the Aromatase Inhibitor, Exemestane, in Human Liver Cytosols and in Patients Treated With Exemestane.
Teslenko I; Trudeau J; Luo S; Watson CJW; Chen G; Truica CI; Lazarus P
J Pharmacol Exp Ther; 2022 Sep; 382(3):327-334. PubMed ID: 35793834
[TBL] [Abstract][Full Text] [Related]
18. Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New Drugs.
Borella E; Poggesi I; Magni P
Clin Pharmacokinet; 2018 Apr; 57(4):505-514. PubMed ID: 28667460
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer.
Hertz DL; Kidwell KM; Seewald NJ; Gersch CL; Desta Z; Flockhart DA; Storniolo AM; Stearns V; Skaar TC; Hayes DF; Henry NL; Rae JM
Pharmacogenomics J; 2017 Dec; 17(6):521-527. PubMed ID: 27549341
[TBL] [Abstract][Full Text] [Related]
20. Impact of UGT2B17 Gene Deletion on the Pharmacokinetics of 17-Hydroexemestane in Healthy Volunteers.
Chen SM; Atchley DH; Murphy MA; Gurley BJ; Kamdem LK
J Clin Pharmacol; 2016 Jul; 56(7):875-84. PubMed ID: 26608382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
